human
ebola
viru
ebov
caus
sever
hemorrhag
fever
diseas
high
mortal
vaccin
treatment
antibodi
survivor
occur
earli
sustain
delay
infect
transfer
nonhuman
primat
monoclon
antibodi
mab
survivor
exhibit
potent
neutral
activ
vitro
protect
rodent
better
understand
target
mechan
neutral
investig
panel
mab
shown
previous
react
envelop
glycoprotein
gp
one
nonneutr
mab
recogn
gp
epitop
nonessenti
mucinlik
domain
rest
specif
neutral
could
distinguish
reactiv
secret
gp
show
survivor
antibodi
human
monkey
specif
conformationdepend
epitop
compris
residu
neutral
occur
two
distinct
mechan
inhibit
cathepsin
cleavag
gp
wherea
recogn
cleav
fusionact
form
gp
ebolavirus
ebov
envelop
nonseg
negativestrand
rna
virus
belong
famili
filovirida
sanchez
et
al
infect
four
five
identifi
speci
includ
zair
zebov
sudan
sebov
ivori
coast
ciebov
recent
discov
bundibugyo
towner
et
al
caus
acut
sever
viral
hemorrhag
fever
diseas
high
mortal
human
anim
reservoir
viru
yet
determin
like
fruit
bat
play
role
natur
cycl
ebov
leroy
et
al
leroy
et
al
center
diseas
control
prevent
classifi
ebov
potenti
biolog
threat
categori
select
agent
rotz
et
al
due
part
high
fatal
rate
potenti
aerosol
transmiss
lack
vaccin
therapeut
treatment
infect
adapt
immun
contribut
protect
ebov
demonstr
use
vaccin
nonhuman
primat
symptom
mortal
rate
resembl
observ
human
infect
bradfut
warfield
bavari
jone
et
al
sullivan
et
al
sullivan
et
al
sullivan
et
al
warfield
et
al
immun
protect
anim
model
associ
develop
cellular
humor
immun
baiz
et
al
gupta
et
al
parren
et
al
takada
et
al
takada
et
al
wilson
et
al
human
survivor
recoveri
associ
earli
vigor
antibodi
respons
long
last
wauquier
et
al
wherea
defect
humor
respons
observ
lethal
case
baiz
et
al
may
consequ
impair
adapt
immun
due
ebov
replic
antigenpres
cell
apc
mahanti
et
al
warfield
et
al
result
delay
antibodi
respons
baiz
et
al
bcell
frequenc
low
mediat
viru
clearanc
sanchez
et
al
altern
antibodi
specif
bind
properti
may
suboptim
effici
viru
clearanc
takada
et
al
takada
et
al
sinc
administr
monoclon
antibodi
confer
protect
rodent
model
lethal
ebov
takada
et
al
takada
et
al
wilson
et
al
identif
neutral
antibodi
nab
mechan
activ
may
import
develop
vaccin
immunotherapi
ebov
sullivan
et
al
central
target
nab
ebov
structur
envelop
glycoprotein
sinc
access
virion
surfac
essenti
viru
entri
chan
et
al
simmon
et
al
takada
et
al
woollewi
bate
woollewi
bate
gp
synthes
polyprotein
posttransl
modifi
two
subunit
membranebound
coval
interact
form
monom
trimer
gp
complex
virion
key
function
domain
potenti
target
nab
put
receptor
bind
domain
rbd
brindley
et
al
kuhn
et
al
manicassami
et
al
howev
access
domain
may
obscur
heavili
glycosyl
mucinlik
domain
muc
serv
major
target
humor
immun
respons
wilson
et
al
pathogen
determin
ebov
infect
dowl
et
al
francica
matukoni
bate
jeffer
sander
sanchez
yang
et
al
unlik
ntermin
rbd
muc
nonessenti
simmon
et
al
takada
et
al
remov
endosom
proteolysi
requir
viru
entri
chandran
et
al
kaletski
simmon
bate
schornberg
et
al
sever
form
gp
identifi
natur
infect
may
serv
target
humor
immun
viral
polymerasedriven
express
ebov
gp
gene
yield
secret
form
gp
sgp
abund
gp
protein
synthes
infect
constitut
greater
total
gp
volchkov
et
al
main
role
viral
pathogenesi
unknown
detect
high
concentr
blood
sanchez
et
al
hypothes
act
immun
decoy
maruyama
et
al
serv
target
viru
specif
antibodi
wilson
et
al
synthesi
full
length
virionbound
gp
direct
polymeras
insert
nontempl
adenosin
transcript
tight
control
gp
express
could
necessari
due
cytopath
effect
exert
protein
express
high
level
cleavag
virionassoci
gp
host
cell
cathepsin
yield
anoth
function
distinct
form
gp
gp
catl
critic
ebov
entri
chandran
et
al
schornberg
et
al
may
expos
critic
ab
determin
within
conserv
domain
rbd
ebov
thought
enter
host
cell
via
receptormedi
endocytosi
clathrinco
pit
caveola
sanchez
viru
entri
affect
chang
endosom
ph
chan
et
al
although
acidif
like
respons
direct
trigger
envelop
protein
classic
phdepend
virus
like
influenza
requir
activ
host
cell
cathepsin
respons
protein
modif
ebov
virus
includ
marburg
viru
sanchez
reoviru
ebert
et
al
sever
acut
respiratori
syndrom
sar
coronaviru
huang
et
al
simmon
et
al
mous
hepat
viru
qiu
et
al
hendra
viru
pager
dutch
nipah
viru
pager
et
al
unlik
sar
coronaviru
endosom
process
cathepsin
necessari
entri
receptor
bind
would
otherwis
render
particl
noninfecti
simmon
et
al
ebov
pretreat
cathepsin
render
stabl
viral
intermedi
fulli
infecti
chandran
et
al
kaletski
simmon
bate
schornberg
et
al
function
cathepsin
ebov
entri
may
analog
bind
hiv
modif
glycoprotein
expos
key
determin
infect
shield
variabl
sequenc
may
otherwis
serv
target
antibodymedi
neutral
therefor
inhibit
cathepsin
cleavag
antibodi
bind
gp
catl
may
provid
addit
target
neutral
ebov
herein
focus
primarili
two
nab
survivor
ebov
infect
explor
function
determin
gp
target
neutral
zebov
gppseudotyp
lentivirus
produc
previous
describ
briefli
human
embryon
kidney
cell
transfect
phrcmvluc
plasmid
vector
use
profect
mammalian
transfect
system
calcium
phosphat
promega
mammalian
vector
encod
gp
zebovmayinga
genbank
access
control
cmv
enhanc
promot
describ
hartikka
et
al
sullivan
et
al
supernat
harvest
h
posttransfect
clear
lowspe
centrifug
filtrat
store
infect
human
umbil
vein
endotheli
cell
huvec
cambrex
highli
infect
ebov
wahljensen
et
al
yang
et
al
presenc
nab
measur
function
luciferas
report
activ
previous
describ
sullivan
et
al
yang
et
al
yang
et
al
briefli
cultur
media
cell
plate
plate
day
prior
infect
replac
pseudotyp
viru
first
incub
hour
presenc
absenc
antibodi
hour
post
infect
cell
lyse
assay
luciferas
assay
system
promega
enzym
activ
determin
use
verita
micropl
luminomet
turner
biosystem
cathepsintr
virion
use
neutral
assay
produc
condit
describ
normal
elisa
catl
proteolysi
gppseudoviru
perform
previous
describ
chandran
et
al
briefli
competit
immunoprecipit
assay
fig
catl
kinet
experi
fig
entri
assay
fig
pellet
pseudoviru
prepar
protein
incub
min
catl
specif
activ
mu
per
mg
calbiochem
acet
buffer
ph
mm
sodium
acet
ph
mm
edta
enzymat
reaction
termin
competit
immunoprecipit
assay
catl
kinet
experi
addit
cathepsin
inhibitor
sigma
boil
respect
mock
treatment
perform
ident
buffer
absenc
enzym
cleav
prepar
analyz
sdspage
use
gel
system
invitrogen
immunoblot
use
rbdspecif
jcb
reagent
use
infect
huvec
viru
entri
assay
gppseudoviru
follow
incub
presenc
absenc
catl
pellet
resuspend
endotheli
cell
growth
medium
lonza
walkersvil
md
prior
infect
huvec
zebovspecif
ab
focu
studi
mous
mab
specif
defin
linear
epitop
muc
recogn
discontinu
epitop
sgp
five
antibodi
protect
mice
mouseadapt
strain
zebov
wilson
et
al
human
recombin
specif
protect
passiv
transfer
guinea
pig
maruyama
et
al
monkey
oswald
et
al
monkey
igg
gpspecif
meissner
et
al
gpspecif
rabbit
control
serum
gener
immun
zebov
gp
jcb
reagent
polyclon
rabbit
serum
monospecif
defin
linear
epitop
ntermin
zebov
amino
acid
zebov
materi
gp
target
mixtur
includ
wt
gppseudoviru
describ
catlcleav
gppseudoviru
describ
free
sgp
harvest
supernat
sgp
z
transfect
cell
prepar
usag
competit
immunoprecipit
assay
ab
incub
immobil
protein
g
plu
pierc
lysi
buffer
contain
proteas
inhibitor
h
room
temperatur
abbead
mixtur
block
normal
calf
serum
normal
goat
serum
addit
h
bead
wash
three
time
lysi
buffer
resuspend
protein
gclear
gp
target
mixtur
sodium
acet
buffer
contain
wild
type
wt
catltreat
gppseudoviru
protein
free
sgp
protein
ip
reaction
least
h
presenc
proteas
inhibitor
sigma
bead
wash
four
time
lysi
buffer
protein
elut
page
load
dye
buffer
min
sampl
analyz
sdspage
western
immunoblot
use
invitrolon
pvdf
membran
pore
size
invitrogen
unconjug
jcb
reagent
use
dilut
detect
wt
gp
sgp
catlprocess
gp
horseradish
peroxidaseconjug
goat
antirabbit
igg
antibodi
santa
cruz
biotechnolog
use
dilut
secondari
detect
densitometri
valu
mean
luminos
protein
band
invert
greyscal
gel
imag
use
adob
san
jose
ca
plasmid
vector
wt
gp
z
sgp
z
describ
pcrdirect
mutagenesi
use
gp
z
vector
profect
mammalian
transfect
system
calcium
phosphat
use
per
manufactur
instruct
promega
transfect
human
embryon
kidney
cell
dulbecco
modifi
eagl
medium
invitrogen
grand
island
ny
supplement
fetal
bovin
serum
fb
invitrogen
antibiot
cell
harvest
hour
posttransfect
use
icecold
pb
invitrogen
contain
mm
edta
gp
mutant
express
cell
use
bind
target
nab
cell
serv
neg
control
abbind
assess
fac
surfac
express
wt
gp
protein
low
sinc
wt
protein
extrem
toxic
protein
mainli
secret
sinc
mutat
affect
coval
associ
jeffer
sander
sanchez
immunostain
procedur
describ
previous
sullivan
et
al
transfect
cell
stain
unlabel
control
gpspecif
rabbit
serum
mab
secondari
detect
antibodi
includ
peconjug
donkey
antihuman
igg
detect
jackson
immunoresearch
laboratori
sheep
antimous
igg
goat
antirabbit
igg
sigmaaldrich
express
empti
plasmid
vector
cell
use
control
nonspecif
abreact
live
cell
acquir
becton
dickenson
lsr
ii
bd
immunocytometri
system
analyz
use
flowjo
softwar
tree
star
ashland
valu
report
mean
sem
comparison
mfi
mutant
wt
fig
complet
anova
post
hoc
dunnett
test
adjust
multipl
comparison
one
control
group
wt
gp
statist
analysi
carri
use
statist
packag
social
scienc
spss
chicago
il
gain
better
understand
viral
target
mechan
neutral
humor
immun
studi
set
select
ebovspecif
antibodi
three
mous
mab
confer
protect
mouseadapt
strain
ebov
wilson
et
al
one
human
mab
lee
et
al
protect
guinea
pig
monkey
oswald
et
al
one
monkey
mab
previous
shown
vitro
analysi
react
ebov
meissner
et
al
neutral
studi
perform
use
ebov
gppseudotyp
retrovir
particl
contain
luciferas
report
gene
assess
inhibitori
capac
antibodi
fig
ebov
gp
viral
pseudotyp
incub
variou
concentr
mab
one
hour
prior
infect
huvec
cell
primari
cell
type
infect
ebov
wahljensen
et
al
yang
et
al
luciferas
activ
result
pseudoviru
entri
analyz
hour
post
infect
graph
percentag
infect
control
sampl
antibodi
ad
result
mab
extend
previou
data
inhibitori
wilson
et
al
former
two
moder
approxim
neutral
mab
specif
amino
acid
present
gp
muc
interfer
infect
target
cell
also
inhibitori
mab
concentr
thu
result
confirm
neutral
properti
mab
one
ebov
gpbear
target
pseudoviru
sinc
capac
abmedi
neutral
affect
presenc
locat
andor
exposur
respect
bind
epitop
ebov
gp
next
explor
recognit
antibodi
ebov
gp
target
mimick
present
natur
infect
virionbound
gp
trimer
secret
nonessenti
sgp
fusionact
conform
gp
result
proteolyt
cleavag
event
assess
rel
mab
recognit
competit
immunoprecipit
ip
assay
fig
gp
sgp
gp
catl
approxim
kd
respect
ebovgp
viral
pseudotyp
pellet
incub
min
presenc
absenc
catl
enzym
reaction
termin
addit
cathepsin
inhibitor
boil
catlcleav
virion
prepar
serv
sourc
materi
gp
catl
untreat
virion
use
assess
recognit
nativ
gp
gp
gp
catl
free
sgp
harvest
supernat
sgp
z
plasmidtransfect
cell
combin
ip
reaction
equival
target
protein
concentr
determin
immunoblot
ip
reaction
input
materi
input
littl
background
observ
unlabel
bead
control
control
antibodi
known
bind
linear
epitop
muc
wilson
et
al
classifi
nonneutr
figur
exhibit
strong
exclus
reactiv
gp
sgp
gp
catl
latter
speci
complet
lack
amino
acid
present
muc
five
mab
test
immunoprecipit
gp
confirm
overexposur
film
data
shown
neutral
mab
demonstr
variou
bind
prefer
differ
gp
form
neutral
mab
recogn
conform
epitop
gp
sgp
wilson
et
al
found
exhibit
greater
affin
sgp
virion
gp
competit
condit
prefer
sgpbind
mab
like
due
increas
exposur
epitop
sgp
compar
gp
possibl
owe
partial
obstruct
nativ
trimer
ntermin
sgphomolog
residu
muc
slightli
differ
conform
sgp
dimer
gp
trimer
yang
et
al
consist
previou
find
bound
exclus
full
length
gp
competit
condit
expect
sinc
epitop
known
compris
amino
acid
present
lee
et
al
maruyama
et
al
contrast
exhibit
preferenti
recognit
gp
catl
sole
mab
bind
gp
catcleav
conform
increas
exposur
time
confirm
mab
panel
react
cathepsinprocess
gp
competit
condit
data
shown
data
demonstr
epitop
compris
residu
muc
sinc
present
gp
catl
altogeth
competit
immunoprecipit
three
separ
gp
product
natur
ebov
infect
allow
qualit
assess
bind
prefer
epitop
present
differ
form
gp
show
notabl
differ
antibodi
shown
epitop
ebovspecif
nab
express
differenti
gp
product
repres
natur
infect
explor
molecular
basi
differ
detail
molecular
character
nab
epitop
undertaken
end
gross
epitopemap
perform
determin
contribut
amino
acid
ntermin
muc
mab
bind
antibodi
bind
analysi
perform
gp
mutant
broad
delet
ntermin
domain
muc
region
fig
fac
stain
gp
delet
mutant
empti
vectortransfect
express
cell
perform
use
control
serum
sgpgp
signific
bind
ratio
mfi
stain
mutant
wt
gp
observ
control
sgpgp
bind
p
bind
p
expect
nonneutr
mab
known
specif
linear
epitop
muc
wilson
et
al
bind
ablat
muc
domain
absent
neutral
mab
shown
strongli
specif
epitop
also
present
sgp
delet
ntermin
region
elimin
antibodi
bind
fig
similarli
bind
lost
upon
delet
nterminu
expect
lee
et
al
delet
mutat
may
ablat
bind
nab
either
remov
critic
bind
residu
within
epitop
disrupt
conform
requir
epitop
format
latter
explan
like
true
sinc
contact
residu
identifi
cocryst
present
mutant
gp
lee
et
al
remov
highli
glycosyl
muc
contrari
affect
antibodi
recognit
gp
four
nab
inde
bind
form
gp
appear
even
stronger
wt
gp
subset
antibodi
owe
either
increas
cell
surfac
express
level
protein
increas
access
epitop
due
remov
muc
shield
effect
final
remov
amino
acid
present
reveal
notabl
differ
gp
bind
among
nab
recognit
independ
residu
bind
depend
consist
report
contact
residu
gp
antibodi
cocryst
modifi
form
gp
lee
et
al
data
delin
differ
among
ntermin
nab
base
requir
residu
recognit
critic
depend
observ
depend
nab
bind
ntermin
ebov
determin
suggest
antibodi
may
block
infect
interf
essenti
function
associ
portion
gp
receptor
bind
catlcleavag
sinc
preferenti
recogn
full
length
gp
prior
cathepsin
cleavag
ask
whether
might
inhibit
viru
entri
interf
critic
gp
modif
address
question
gppseudoviru
treat
catl
presenc
reaction
termin
variou
time
addit
cathepsin
inhibitor
boil
neg
control
inactiv
heat
mucbind
mab
neutral
data
shown
process
similarli
reaction
product
evalu
sdspage
fig
uncleav
gp
observ
migrat
fragment
gp
time
zero
effici
process
catl
enzym
fig
b
report
previous
chandran
et
al
two
domin
proteolyt
product
observ
result
catl
cleavag
intermedi
fragment
indic
gp
observ
other
kaletski
simmon
bate
schornberg
et
al
final
product
gp
capabl
mediat
membran
fusion
control
reaction
use
either
heat
intermedi
fragment
gp
constitut
minor
transient
cleavag
product
process
complet
fusogen
gp
fig
c
process
fusionact
gp
occur
effici
within
first
minut
complet
within
minut
incub
catl
contrast
presenc
intact
delay
reaction
significantli
complet
proteolysi
achiev
even
minut
incub
result
show
bind
ebov
glycoprotein
inhibit
critic
catl
cleavag
event
requir
format
fusion
activ
gp
addit
biochem
studi
also
perform
use
remain
nab
examin
report
sinc
may
possibl
similar
bind
epitop
compris
residu
either
within
overlap
put
catl
cleavag
site
note
catl
cleavag
unaffect
presenc
mucbind
control
mab
effici
process
observ
likewis
addit
nab
effect
proteolysi
contrast
demonstr
interfer
proteolysi
intermedi
gp
gp
block
gp
process
transient
reaction
eventu
result
complet
proteolyi
gp
data
demonstr
much
lesser
extent
delay
catl
cleavag
suggest
capac
may
contribut
part
neutral
activ
show
recogn
epitop
determin
depend
presenc
residu
also
confirm
lee
et
al
bind
properti
two
nab
differenti
prefer
bind
catlprocess
gp
exhibit
exclus
therefor
examin
next
capac
antibodi
panel
block
entri
mediat
catlcleav
ebov
gppseudoviru
fulli
infecti
chandran
et
al
kaletski
simmon
bate
catltreat
pseudovirion
incub
one
hour
presenc
mab
variou
concentr
rang
one
hour
prior
infect
huvec
cell
luciferas
activ
measur
hour
later
fig
mab
neutral
gppseudoviru
fig
capabl
effici
block
transduct
catlgp
pseudovirus
lack
neutral
consist
preferenti
reactiv
antibodi
nativ
precleav
gp
shown
figur
lack
catlgp
recognit
thu
although
demonstr
depend
bind
similar
determin
within
gp
abl
bind
neutral
catlprocess
gpbear
pseudovirus
data
suggest
may
neutral
pseudoviru
distinct
stage
entri
process
may
help
explain
reduc
potenc
observ
neutral
virion
bear
nativ
gp
shown
figur
order
gain
better
understand
target
mechan
ebov
nab
studi
panel
known
ebovspecif
antibodi
three
mous
mab
confer
protect
mice
mouseadapt
ebov
wilson
et
al
one
human
mab
lee
et
al
protect
guinea
pig
monkey
oswald
et
al
one
monkey
survivor
mab
specif
gp
meissner
et
al
nterminu
contain
put
rbd
requir
receptor
bind
viru
fusion
brindley
et
al
kuhn
et
al
manicassami
et
al
therefor
may
serv
potent
target
nab
neutral
mab
examin
herein
epitop
compris
ntermin
amino
acid
sinc
delet
ntermin
region
ablat
abbind
nab
could
segreg
base
depend
residu
within
requir
presenc
recognit
capabl
bind
free
sgp
contain
residu
thu
would
reason
hypothes
bind
ntermin
specif
ab
may
interfer
number
event
requir
viru
entri
includ
cell
attach
receptor
bind
andor
membran
fusion
noteworthi
bind
determin
access
sgp
virion
gp
figur
suggest
weaker
bind
affin
nativ
gp
may
explain
reduc
potenc
neutral
compar
addit
note
efficaci
nab
recogn
free
sgp
like
may
diminish
vivo
fact
ligand
greatest
affin
sgp
present
higher
frequenc
virusassoci
gp
natur
infect
may
form
complex
deplet
antibodi
specif
contrari
recognit
gp
also
depend
amino
acid
present
ntermin
bind
depend
presenc
residu
present
sgp
bind
result
consist
contact
identifi
cocryst
reveal
specif
residu
situat
distant
locat
put
rbd
lee
et
al
previous
known
mab
bridg
attach
fusion
subunit
viral
gp
lee
et
al
present
find
identifi
anoth
antibodi
similar
properti
neutral
studi
herein
reveal
mab
examin
one
capabl
neutral
ebov
gpbear
pseudoviru
vitro
lack
neutral
predict
sinc
studi
mice
show
protect
passiv
transfer
wilson
et
al
howev
quit
possibl
protect
observ
model
may
influenc
use
seriallypassag
viru
adapt
infect
nonnatur
host
speci
adult
mice
natur
resist
ebov
infect
import
biolog
differ
viral
patholog
gp
amino
acid
sequenc
mouseadapt
virus
may
affect
recapitul
clinic
sever
also
protect
could
mediat
altern
mechan
distinct
interfer
viru
entri
antibodydepend
cellmedi
cytotox
adcc
lack
neutral
mucdirect
report
consist
model
wherebi
ebov
muc
express
protect
role
antibodi
bind
unlik
glycan
shield
hiv
protect
receptor
bind
domain
nab
wei
et
al
sinc
put
rbd
ebov
recess
beneath
glycan
cap
lee
et
al
domain
complet
dispens
infect
simmon
et
al
takada
et
al
immunodomin
humor
respons
nonleth
ebov
infect
sinc
major
ebovspecif
ab
report
date
recogn
continu
epitop
region
wilson
et
al
like
result
muc
compris
expos
element
virusbound
gp
vanderzanden
et
al
thu
valu
domain
protect
critic
function
region
humor
immun
seem
evid
although
bound
epitop
depend
amino
acid
abl
bind
neutral
cathepsinprocess
gppseudovirus
result
demonstr
recogn
critic
neutral
determin
differenti
access
nativ
catlcleav
gp
mechan
neutral
consist
model
wherebi
bind
occur
either
endosom
compartment
block
trigger
final
activ
form
gp
may
requir
particip
cellular
reductas
schornberg
et
al
anoth
cofactor
fusion
event
downstream
event
requir
viru
entri
moreov
data
demonstr
may
also
exhibit
capac
catl
inhibit
virtu
proxim
gp
cleavag
site
addit
primari
mechan
neutral
describ
herein
howev
sinc
mechan
ebov
entri
yet
fulli
character
difficult
predict
point
viru
entri
neutral
determin
access
antibodi
date
first
mab
describ
preferenti
bind
catl
cleav
form
ebov
gp
importantli
characterist
associ
greater
potenc
neutral
albeit
higher
mab
concentr
antibodi
studi
sinc
potent
higher
concentr
neutral
viru
vitro
antibodymedi
interfer
catl
cleavag
alon
may
effect
neutral
viru
block
mechan
act
later
event
requir
fusion
observ
addit
catl
cleavag
eventu
progress
despit
bind
follow
longer
incub
period
rais
possibl
leaki
could
explain
observ
viru
escap
passiv
transfer
macaqu
data
directli
explain
passiv
transfer
alon
fail
protect
monkey
lethal
viru
challeng
oswald
et
al
suggest
mechan
may
suboptim
potent
vivo
neutral
compar
multipl
neutral
activ
exhibit
sinc
bind
catlprocess
gp
inhibit
catlcleav
viral
pseudotyp
hypothes
proteolyt
cleavag
critic
requir
viral
entri
chandran
et
al
may
act
disrupt
bind
epitop
ablat
bind
may
possibl
occur
remov
contact
residu
disrupt
gp
conform
inde
presenc
suffici
inhibit
format
critic
fragment
requir
viral
entri
larger
intermediari
fragment
contain
rbd
observ
fragment
intermedi
gp
intermedi
cathepsin
proteolysi
observ
kaletski
simmon
bate
schornberg
et
al
data
herein
show
ebov
gp
contain
least
two
separ
catl
cleavag
site
gp
cleavag
site
occur
muc
yield
fragment
contain
rbd
second
catl
cleavag
site
gp
like
occur
somewher
muc
furthermor
due
proxim
bind
site
presumpt
rbd
contribut
direct
receptor
antagon
ab
discount
entir
thu
data
consist
model
abmedi
neutral
wherebi
interfer
cathepsin
cleavag
gp
block
enzym
attach
activ
hinder
cathepsinactiv
fusogen
form
gp
contain
rbd
receptor
bind
directli
conclus
show
first
time
two
neutral
ab
inhibit
viral
transduct
two
fundament
differ
mechan
neutral
exploit
ebov
requir
endosom
proteolysi
requir
viru
entri
contrari
express
classic
mechan
abmedi
neutral
inhibit
trigger
fusogen
gp
fusion
event
andor
receptor
bind
addit
nab
also
exhibit
moder
capac
inhibit
catl
proteolysi
ebov
gp
sinc
current
vaccin
treatment
ebov
diseas
futur
vaccin
strategi
may
effect
provis
antibodi
like
recogn
postcleavag
gp
remain
determin
whether
provid
protect
vivo
evalu
futur
studi
inform
ebov
gp
viral
pseudotyp
incub
variou
concentr
mous
human
monkey
one
hour
prior
infect
huvec
cell
luciferas
activ
read
hour
post
infect
graph
infect
rel
infect
absenc
antibodi
error
bar
repres
sem
b
competit
ip
natur
gp
product
infect
wt
catlprocess
gp
catl
gpbear
pseudoviru
sgp
ip
materi
control
input
ip
sampl
analyz
sdspage
western
immunoblot
use
jcb
antibodi
reagent
detect
experi
perform
independ
least
three
time
similar
result
